About MetaVi Labs, Inc.
MetaVi Labs accelerates cancer research using cutting-edge computer vision tools. We empower researchers to use direct observation to accurately quantify and objectively analyze cancer cells, immune cells, and their interactions. Our focus is cancer drug discovery.
Automated Tracking of Free-Roaming Cells in 3D Collagen
As he pioneered the discovery of the anti-metastatic effect of beta blockers on tumor cell migration, MetaVi Labs Co-founder Frank Entschladen collaborated with fellow Co-founders David Drell, Andy Thysen, and Theodore Drell to automate cell tracking. From this collaboration, MetaVi Labs was born. See the original 3D collagen tracking videos and report here.
2013 (and ongoing)
Myelodsyplastic Syndromes Diagnosis with Neutrophil motility in peripheral blood
In cooperation with Prof. M. Gunzer and Germing/Möller, UH Düsseldorf
Partnered with ibidi
Established a distribution partnership with ibidi, the developer of advanced products for functional cell-based assays and cell microscopy.
Launched Tumor Spheroids Tracking for Individual Patient Treatment Optimization
In cooperation with Prof. Peter Friedl MD Anderson/Radboud Univ (The Netherlands), EU MULTIMOT Project.
Launched commercially available angiogenesis-tube formation analysis reporting system to the market.
Launched Wound Healing, Angiogenesis Tube Formation and High Content Analyses Systems. Sold via ibidi.
Launched Chemotaxis Assay
Launched the premiere chemotaxis assay tracking solution on the market today.
MetaVi Labs ACAS—Automated Cellular Assay System—now in use by over 300 labs.
Over 300 labs are tracking their Angiogenesis Tube Formation, Wound Healing, and Sheroid images with MetaVi Labs.
Introduces Pathotaxis Assay Tracking
Pioneered by MetaVi Labs, Pathotaxis is a new method of tracking the movement of immune cells toward cocultured pathogens while quantifying velocity, synapse formation, apoptosis, and serial killing.